DESIR Cohort 10-year data (OP0102): SIJ structural lesions in #axSpA progress slowly, but prior MRI bone marrow oedema p

      Antoni Chan MD (Prof) synovialjoints

      1 week ago
      DESIR Cohort 10-year data (OP0102): SIJ structural lesions in #axSpA progress slowly, but prior MRI bone marrow oedema predicts later structural damage. bDMARD exposure was associated with less erosion progression supporting early biologic treatment Abstr OP0102 @RheumNow
      After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival

      Jiha Lee JihaRheum

      1 week ago
      After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival at 12m) and axSpA (80% vs 68%), but not RA. Yet 74% of axSpA pts still got another TNFi. Evidence vs practice gap in plain sight. @RheumNow #EULAR2026 POS0776
      #OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower over

      Mrinalini Dey DrMiniDey

      1 week ago
      #OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower overall cancer risk vs shorter exposure, esp for haematologic malignancies. Data add to long-term safety evidence for targeted therapies in SpA. #EULAR2026 @RheumNow
      After failure of a first TNFi in axSpA, #OP0235 from ROC-SpA trial found no superiority of switching to an IL-17A inhibi

      Mrinalini Dey DrMiniDey

      1 week ago
      After failure of a first TNFi in axSpA, #OP0235 from ROC-SpA trial found no superiority of switching to an IL-17A inhibitor over cycling to second TNFi. ASAS40 responses at Week 24 similar with both strategies, supporting individualised treatment decisions. #EULAR2026 @RheumNow
      What to use in #RA #IL6i v #abatacept post #TNFi-IR?
      H2H #TCZ v #Abatacept

      Same on primary outcome
      #CDAI change wk26
      BU

      Janet Pope Janetbirdope

      1 week ago
      What to use in #RA #IL6i v #abatacept post #TNFi-IR? H2H #TCZ v #Abatacept Same on primary outcome #CDAI change wk26 BUT If #monoRx TCZ better Better retention #TCZ So you decide which is better! Equal v some advantages w #tocilizumab #EULAR2026 @RheumNow @eular_org #OP0205 https://t.co/xdOx4kQCTC
      RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA
      -Primary endpoint DAS28-CRP change wk12
      -2.06 to -2.12 (all doses)

      Aurelie Najm AurelieRheumo

      1 week ago
      RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA -Primary endpoint DAS28-CRP change wk12 -2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01 -ACR20/50/70 + CDAI LDA all improved vs PBO -hsCRP reduction across all dose arms -69% CDAI LDA by wk14 -wk 28 extension shows https://t.co/AMfmSded0D
      A new MoA that does not meet it's primary endpoint in RA

      SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib

      ACR2

      Aurelie Najm AurelieRheumo

      1 week ago
      A new MoA that does not meet it's primary endpoint in RA SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib ACR20 wk12 NOT significantly diff vs PBO ~48.5–61.8% across doses vs 52.3% PBO Secondary BALI 200 mg QD: ACR50: 36.9% vs 18.5% (nominal p=0.0179) Mechanistic https://t.co/hmZ93JisiO
      EULAR flags
      Understanding Comorbidities in RMD
      • 2026 EULAR Press Release
      1 week ago
      People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
      Roc-SpA study
      Active axSpA dse + inad response to TNFi ➡️switch or cycled
      No significant diff in ASDAS40 at wk24 bet

      sheila RHEUMarampa

      1 week ago
      Roc-SpA study Active axSpA dse + inad response to TNFi ➡️switch or cycled No significant diff in ASDAS40 at wk24 bet IL-17i & 2nd TNFi Switching to IL-17i not superior to cycling to 2nd TNFi after inad. response to 1st TNFi Shared decision is key AbsOP0235 @RheumNow #EULAR2026 https://t.co/3UP37IEgXv
      What if we let RA patients choose ttmt?

      BACH RCT choice between Filgo / scTNFi vs. standard randomisation
      55% JAKi vs 4

      Aurelie Najm AurelieRheumo

      1 week ago
      What if we let RA patients choose ttmt? BACH RCT choice between Filgo / scTNFi vs. standard randomisation 55% JAKi vs 45% TNFi Higher ttmt satisfaction 46 vs 33 p=0.012 Less ttmt switches 6 vs 15 p=0.026 Less AE reported Better drug survival Shared decision making is key! https://t.co/1YS0y6YUEH
      Is there a ‘window
      Of opportunity’ for Rx
      #GCA w #IL6i
      🤞
      Obtain a better response

      Rx GCA #GC
      #TCZ
      #Upadacitinib

      Janet Pope Janetbirdope

      1 week ago
      Is there a ‘window Of opportunity’ for Rx #GCA w #IL6i 🤞 Obtain a better response Rx GCA #GC #TCZ #Upadacitinib #MTX Study tries to answer if effects of #tocilizumab early vs >8wks is diff N=471, 19% new GCA Early vs late TCZ no dif ❎No Not RCT POS0624 #EULAR2026 @RheumNow
      📈 Do SIJ lesions progress in #axSpA?

      DESIR cohort (n=649, 10yrs):
      Yes, slowly, but bDMARDs reduce erosion progressi

      Nelly ZIADE 🍀 Nellziade

      1 week 1 day ago
      📈 Do SIJ lesions progress in #axSpA? DESIR cohort (n=649, 10yrs): Yes, slowly, but bDMARDs reduce erosion progression #OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4
      🔍Can early TNFi beat step-up csDMARDs in pSpA?

      SPARTACUS RCT (n=97) says YES
      60% vs 33% remission at 24 wks

      #EULAR2

      Nelly ZIADE 🍀 Nellziade

      1 week 1 day ago
      🔍Can early TNFi beat step-up csDMARDs in pSpA? SPARTACUS RCT (n=97) says YES 60% vs 33% remission at 24 wks #EULAR2026 @rheumnow #OP0107 https://t.co/1odtcRdTLQ
      Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+
      safety data
      JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
      1 week 1 day ago
      Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.

      Catch up on Conference Podcasts

      ×